17b-hydroxysteroid

structural basis     biological validation     computational study     hydroxysteroid dehydrogenase type     specie specific inhibition     human enzyme     elegant strategy     intracellular estradiol concentration     non-steroidal inhibitor     different non-steroidal inhibitor class     computational method     conformational change     molecular docking     specie specific inhibition profile     selected member     estrogen dependent disease     small a-helix     homology modelling     structurebased drug design     reasonable model     ortholog protein     potent estrogen     17b-hydroxysteroid dehydrogenase type     promising approach     inhibitory potency     inhibition data     active site topology     energy calculation     distinct knowledge     md simulation     cocrystal structure     protein-ligand interaction     various specie     three-dimensional structure     inhibition value     several steroidal    

In the present study, expressions of 17B-hydroxysteroid dehydrogenase (17HSD) types 1, 2 and 3, 5α-reductase type 2 and human androgen receptor mRNAs were determined in 12 benign prostatic hyperplasia and 17 prostatic carcinoma specimens. 17HSD type 2 was found to be the principal isoenzyme expressed in the prostate. Significantly higher expressions of 17HSD type 2 and 5α-reductase type 2 were detected in benign prostatic hyperplasia compared with the carcinoma specimens. Expression of the androgen receptor in the 2 groups was not significantly different. 17HSD type 3 mRNA was not detected in any of the specimens investigated. Only low constitutive expression of the kb mRNA of 17HSD type I was seen. Immunohistochemical analyses indicated that this did not lead to significant enzyme expression, only faint staining for the enzyme protein being detected, mainly in uroepithelial cells. No significant correlation was found between any of the mRNAs analyzed, but the data on 5α-reductase type 2 mRNA support the presence of an increased proportion of 5α-dihydrotesterone in the hyperplastic prostate. In cultured PC-3 prostatic cancer cells and in transiently transfected human embryonic kidney 293 cells, 17HSD type 2 was found exclusively to convert 5α-dihydrotestosterone and testosterone into the less potent 17-keto compounds 5α-androstanedione and 4-androstenedione, respectively. We suggest that the 17HSD type 2 isoenzyme plays a part in the metabolic pathway, resulting in the inactivation of testosterone and 5α-dihydrotestosterone locally in the prostate. The enzyme expressed in the prostate could, therefore, protect cells from excessive androgen action. © 1996 Wiley-Liss, Inc.

17b-hydroxysteroid

17b-hydroxysteroid

Media:

17b-hydroxysteroid17b-hydroxysteroid17b-hydroxysteroid17b-hydroxysteroid17b-hydroxysteroid

http://buy-steroids.org